Labrys Biologics was a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Mateo, California, developing monoclonal antibody therapeutics targeting calcitonin gene-related peptide (CGRP) for the prevention of chronic and episodic migraine. The company was venture-backed, with Canaan Partners among its investors, and was acquired by Teva Pharmaceutical Industries in 2014, after which its lead anti-CGRP antibody program continued under Teva. Labrys Biologics no longer operates as an independent company and maintains no developer or API surface: enrichment probes on 2026-07-19 found the registrant domain labrysbiologics.com resolving but serving nothing (TCP 80 and 443 closed), delegated to Teva nameservers, with a no-mail SPF/DMARC lockdown and no GitHub organization. This profile is retained as a historical portfolio-company record rather than an API listing.
Labrys Biologics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Therapeutics.
aid: labrys-biologics
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/labrys-biologics.png
name: Labrys Biologics
description: 'Labrys Biologics was a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Mateo,
California, developing monoclonal antibody therapeutics targeting calcitonin gene-related peptide (CGRP) for the prevention
of chronic and episodic migraine. The company was venture-backed, with Canaan Partners among its investors, and was acquired
by Teva Pharmaceutical Industries in 2014, after which its lead anti-CGRP antibody program continued under Teva. Labrys
Biologics no longer operates as an independent company and maintains no developer or API surface: enrichment probes on 2026-07-19
found the registrant domain labrysbiologics.com resolving but serving nothing (TCP 80 and 443 closed), delegated to Teva
nameservers, with a no-mail SPF/DMARC lockdown and no GitHub organization. This profile is retained as a historical portfolio-company
record rather than an API listing.'
url: https://raw.githubusercontent.com/api-evangelist/labrys-biologics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: teva
x-acquired-year: 2014
x-operating: false
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- Neurology
- Clinical Research
- Acquired
apis: []
common:
- type: DomainSecurity
url: security/labrys-biologics-domain-security.yml
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.